Musclederived expression of the chemokine CXCL1 attenuates diet-induced obesity and improves fatty acid oxidation in the muscle. Am J Physiol Endocrinol Metab 302: E831-E840, 2012. First published January 24, 2012; doi:10.1152/ajpendo.00339.2011.-Serum levels and muscle expression of the chemokine CXCL1 increase markedly in response to exercise in mice. Because several studies have established musclederived factors as important contributors of metabolic effects of exercise, this study aimed at investigating the effect of increased expression of muscle-derived CXCL1 on systemic and intramuscular metabolic parameters, with focus on fatty acid oxidation and oxidative metabolism in skeletal muscle. By overexpression of CXCL1 in the tibialis cranialis muscle in mice, significant elevations in muscle and serum CXCL1 within a physiological range were obtained. At 3 mo of high-fat feeding, visceral and subcutaneous fat mass were 32.4 (P Ͻ 0.01) and 22.4% (P Ͻ 0.05) lower, respectively, in CXCL1-overexpressing mice compared with control mice. Also, chow-fed CXCLtransfected mice had 35.4% (P Ͻ 0.05) lower visceral fat mass and 33.4% (P Ͻ 0.05) lower subcutaneous fat mass compared with chow-fed control mice. These reductions in accumulation of adipose tissue were accompanied by improved glucose tolerance and insulin sensitivity. Furthermore, in CXCL1-transfected muscles, muscular ex vivo fatty acid oxidation was significantly enhanced compared with control muscles (chow fed: 2.2-fold, P Ͻ 0.05; high-fat fed: 2-fold, P Ͻ 0.05) and also showed increased expression levels of major fatty acid oxidation genes (CD36, CPT I, and HADH). Finally, CXCL1 expression was associated with increased muscle mRNA expression of VEGF and CD31, suggesting a role for CXCL1 in muscle angiogenesis. In conclusion, our data show that overexpression of CXCL1 within a physiological range attenuates diet-induced obesity, likely mediated through a CXCL1-induced improvement of fatty acid oxidation and oxidative capacity in skeletal muscle tissue. myokines; keratinocyte-derived chemokine; growth-related oncogene-␣ SINCE THE DISCOVERY OF IL-6 as the first identified myokine, it has been recognized that skeletal muscle contractile activity increases the production and release of a variety of different cytokines ("myokines"). Today, the list of verified myokines includes IL-6, leukemia inhibitory factor, fibroblast growth factor 21, and follistatin-like-1 (4). Research has revealed that myokines exert autocrine, paracrine, and/or endocrine effects, and several studies have established a role of these musclederived factors as important contributors of the beneficial effects of exercise. Among other things, evidence suggests that myokines contribute toward improved intramuscular and whole body fatty acid oxidation, increase lipolysis (4, 5, 35, 37), and enhance glucose metabolism in muscles (10). Because the myokine paradigm thereby provides a conceptual basis explaining the numerous beneficial adaptations of a physically active lifestyle, further insight into the effects of new potential myokines is of major importance.
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Recently, we and others reported that exercise induces an increase in murine chemokine CXC motif ligand 1 (CXCL1), also known as keratinocyte-derived chemokine (KC), in skeletal muscle and in serum (20, 26) , suggesting that CXCL1 potentially acts as an exercise-induced myokine. CXCL1 belongs to the glutamate-leucine-arginine (ELR)-containing CXC chemokine family. Murine CXCL1 shares the highest sequence homology with human CXCL1/growth-related oncogene-␣ (GRO␣) (90% homology in conserved regions) (22) , but as judged by its pattern of expression and putative function, CXCL1 is suggested to be a closer functional equivalent of human IL-8 (18, 29, 30) . The plasma concentration of IL-8 and other chemokines increases in response to exercise in humans (23) . IL-8 is a potent angiogenic factor (1), but little is known about the physiological role of exercise-induced IL-8. The newly identified exercise-factor CXCL1 is known primarily for its role in inflammation, chemotaxis, and angiogenesis (16, 31) , for its neuroprotective effects (24) , and as a promoter of tumor growth (8, 9) . Thus, the metabolic role of muscle-derived CXCL1 still remains to be investigated. Therefore, the present study was undertaken to examine the effect of increased expression of muscle-derived CXCL1 on systemic and intramuscular metabolic parameters, with focus on fatty acid oxidation and oxidative metabolism in skeletal muscle. The metabolic effects of elevated muscle and serum CXCL1 were investigated utilizing an in vivo mouse model with electrotransfer-mediated CXCL1 overexpression in the tibialis cranialis muscle. We show that overexpression of muscle CXCL1 attenuates diet-induced fat accumulation and that this effect is associated with increased ex vivo fatty acid oxidation and CXCL1-dependent upregulation of genes involved in fatty acid oxidation and vascularization in the muscle. Hence, this study provides evidence that CXCL1 is a likely contributor to some of the anticipated beneficial adaptations in skeletal muscle and concomitant health effects of regular physical activity.
MATERIALS AND METHODS

Ethics
All animal experiments were conducted in accordance with the recommendations of the European Convention for the Protection of Vertebrate Animals used for Experimentation and after permission was given by the Danish Animal Experiments Inspectorate.
CXCL1-Electrotransfected Mice
Overexpression of CXCL1 was obtained by electrotransfer of a plasmid encoding CXCL1 into the tibialis cranialis muscle in 8-wkold C57Black/C mice (Taconic), as described previously (13) . The pBI-CXCL1 encoding murine CXCL1 (accession no. NM_008176.3) under control of a Tet-On dependent promoter was cloned by GeneArt (Regensburg, Germany) (Vector accession no. U89932). DNA preparations were performed using QIAfilter Plasmid Maxiprep kits (Qiagen, Hilden, Germany). In short, anesthetized mice were injected intramuscularly with 20 l of plasmid solution (0.5 g/l) and electropulsed using 4-mm plate electrodes and electric parameters of one high-voltage pulse (100 s, 800 V/cm) and one low-voltage pulse (400 ms, 100 V/cm). Electroporation procedure using these parameters has previously been documented as safe, with only small transient disturbances in ion balance, ATP content, and contractile force, which is restored 4 h after the treatment. Furthermore, gene expression profiling shows that gene expression levels show modest changes as a consequence of the procedure (12, 14) . Induction of gene expression was obtained by administering drinking water containing 0.2 mg/ml doxycycline (doxycycline hyclate; Sigma-Aldrich) immediately after electrotransfer. Control mice were injected with either 20 l of saline or an empty pBI vector ϩ TetOn vector solution prior to electropulsing [the empty pBI vector control was applied only in the dual-energy X-ray absorptiometry (DEXA) and magnetic resonance (MR) experiment; see below]. The mice had free access to food and drinking water and were housed in a thermostated environment on a 12:12-h light-dark cycle. One-half of the CXCL1-transfected mice and onehalf of the control group were fed a standard maintenance diet (normal chow, 2,844 kcal/kg, 4% crude fat, Altromin pellets; SpezialfutterWerke). The other half of the CXCL1-transfected mice and of the control group were fed a high-fat diet containing 60 kcal% fat (high fat, 5,240 kcal/kg, 34.9% crude fat; Research Diets, Bomholtgaard, Denmark). At euthanasia, blood samples were drawn, and intact liver, tibialis cranialis muscle, visceral adipose tissue, and subcutaneous adipose tissue were immediately dissected and frozen in liquid nitrogen. The subcutaneous fat deposits were dissected by removing the encapsulated fat pad located in the right flank, whereas the abdominal fat deposits were isolated by insertion into the peritoneal cavity and by dissecting out the fat pad associated with the uterus and ovaries. The adipose tissue was then isolated from the nonadipose structures.
Body Composition
Total body weight and food intake were assessed from the day of transfection and consumption calculated. Three months after CXCL1 transfection, the mice were euthanized and weight of the different intact organs (frozen) was measured.
In CXCL1-transfected mice and in control mice transfected with an empty pBI vector, total fat mass and lean body mass were assessed densitometrically by dual-energy X-ray absorptiometry (DEXA) measurements and by nuclear magnetic resonance (MR) spectroscopy (MR scanning) 8 wk after electrotransfection. Mice were anesthetized, weighed, and DEXA scanned five times using a human peripheral densitometer (Lunar PIXImus, software version 1.42.006.010; Lunar, Madison, WI) outfitted with small-animal software. Groups of eight animals were placed side by side on the imaging positioning tray. Data collection for each mouse was obtained by placing a region of interest around each mouse as described in the instructions provided by the manufacturer. All DEXA determinations and analysis were performed by one investigator using the software provided by the manufacturer. Immediately after DEXA analysis, mice were euthanized by cervical dislocation. A MR scan of each mouse was then performed by use of nuclear MR spectroscopy technology produced by Echo Medical Systems (EchoMRI-4in1Tm QMR System; Echo Medical Systems, Houston, TX). Mice were placed in a tube and analyzed on the accumulation 4 setting, which is specific for mice, to determine total fat mass, lean mass, and water content.
Blood Analysis
Insulin tolerance test. Insulin tolerance test (ITT) was performed 10 wk after CXCL1 transfection. The mice were fasted for 5 h and then challenged with an intraperitoneal load of insulin (0.5 mU/g insulin diluted in 0.9% sterile saline). Blood samples (10 l) were taken from the retroorbital vein from conscious mice, and blood glucose was measured at 0 min (prior to insulin injection) and 15, 30, and 60 min after the insulin load using the HemoCue Glucose 201ϩ system (HemoCue). After 60 min, blood glucose level had reached a critical minimum, and the mice were injected intraperitoneally with glucose solution to reestablish their blood glucose level.
Glucose tolerance test. Twelve weeks after CXCL1 transfection, a glucose tolerance test (GTT) was performed. Mice were fasted overnight for 16 h and then injected intraperitoneally with 2 mg/g body wt glucose (diluted in 0.9% sterile saline). Blood samples (10 l) were taken from the retroorbital vein, and blood glucose was measured at 0, 30, and 120 min after the glucose load using the HemoCue Glucose 201ϩ system (HemoCue).
Serum cytokines. Three months after CXCL1 transfection, 500 l of blood were drawn at euthanasia and processed to serum. A MesoScaleDiscovery (MSD) multiplex platform (MesoScaleDiscovery) precoated with CXCL1, IL-6, IL-1␤, INF␥, IL-10, IL-12, and TNF␣ capture antibodies was used according to the manufacturer's protocol. The MSD plate was measured on a MSD Sector Imager 2400 plate reader. Raw data were measured as electrochemiluminescence signal (light) detected by photodetectors and analyzed using the Discovery Workbench 3.0 software (MSD). A four-parameter logistic fit curve was generated for each analyte using the standards and the concentration of each sample calculated. The sensitivity of each of the analytes was as follows: CXCL1, 3.3 pg/ml; IL-6, 4.5 pg/ml; IL-1␤, 0.75 pg/ml; IL-10, 11 pg/ml; IL-12, 35 pg/ml; INF␥, 0.38 pg/ml; and TNF␣, 0.85 pg/ml. For each analyte, the coefficient of variation was Ͻ10%.
Serum metabolites. Serum-free glycerol and free fatty acids (FFA) were measured using color end point assays (Zenbio, cat no. GFA-1) according to the manufacturer's protocol. A 20-l sample for glycerol determination and a 10-l sample for FFA determination were used. Optical density was measured spectrophotometrically at 540 nm after 15 min of incubation at room temperature for the glycerol assay and 10 min of incubation at 37°C for the FFA assay after the addition of all provided reagents. Optical density of each well was determined at 540 nm with an automated FLUOstar Optima plate reader (BMG Labtech, Offenburg, Germany). A standard curve was generated on the basis of a serial dilution of 1 mM glycerol or FFA (palmitate) and concentration of each sample calculated.
RT-Quantitative PCR
Reverse transcription. Total RNA was isolated from frozen tissues by tissue homogenization and RNA extraction using TRIzol reagent (Invitrogen Life Technologies). Purity and concentration of the RNA samples were determined using a Nanodrop spectrophotometer. Reverse transcription was performed using MultiScripe Reverse Transcriptase (High-Capacity cDNA Reverse Transcription Kit; Applied Biosystems) and random p(dN)6 primers (Applied Biosystems), following the manufacturer's instructions.
Real-time PCR. All amplifications were carried out in a final volume of 10 l with 3 l of cDNA, using the SYBR Green PCR Master Mix (Applied Biosystems) and sequence-specific primers. Quantitative PCR and detection were performed using the ABI 7900 Sequence Detection System (Applied Biosystems). Quantification was performed using the comparative threshold cycle method. Expression of the different target genes was normalized to the corresponding expression level of housekeeping gene 18S. Expression level of 18S was found to not differ between groups. The efficiency of each individual plate assay and primer pair was observed continuously by inclusion of standard curves on each plate to ensure a comparable efficiency of 99 -101%. Dissociation curve analysis was performed after each PCR to check for unspecific signals.
Homogenate Oxidations
A 2-wk in vivo CXCL1 transfection study performed as described above was applied to determine palmitate oxidation in the transfected muscles. Palmitate oxidation was measured in muscle homogenates using a modified method of that described by Turner et al. (36) . Briefly, muscles were homogenized in 19 volumes of ice-cold 250 mmol/l sucrose, 10 mmol/l Tris·HCl, and 1 mmol/l EDTA, pH 7.4, immediately after dissection. For assessment of substrate oxidation, 50 l of muscle homogenate was incubated with 450 l of reaction mixture (pH 7.4). Final concentrations of the reaction mixture were (in mmol/l) 100 sucrose, 80 KCl, 10 Tris·HCl, 5 KH 2PO4, 1 MgCl2, 2 malate, 2 ATP, 1 dithiothreitol, 0.2 EDTA, and 0.3% fatty acid-free BSA. Substrates were 0.2 mmol/l [1-
14 C]palmitate (0.5 Ci) plus 2 mmol/l L-carnitine and 0.05 mmol/l coenzyme A. After 90 min of incubation at 30°C, the reaction was stopped by the addition of 100 l of 1 mol/l perchloric acid. CO 2 produced during the incubation was collected in 100 l of 1 mol/l NaOH. For palmitate incubations, 14 C counts present in the acid-soluble fraction were also measured and combined with the CO2 values to give the total palmitate oxidation rate.
Protein Determination in Muscle Homogenates
Protein concentration of muscle homogenates was determined in triplicate using the bicinchoninic acid method and bicinchoninic acid assay reagents (Pierce). A maximal coefficient of variance of 5% was accepted between replicates.
Histological Analysis of CXCL1-Transfected Muscle
A 5-wk CXCL1 transfection study as described above was applied. Intact tibialis cranialis muscles were dissected, fixed in 1 ml of formalin buffer, and embedded in paraffin blocks, following standard procedures. Sections 3-5 m thick were stained with hematoxylin and eosin staining (routine staining) and alkaline phosphatase-conjugated CD31 antibodies (immunohistological preparation).
Statistical Analysis
Two-way ANOVA was used to test the effect of CXCL1 transfection combined with normal chow or high-fat diet. If analyses revealed a significant interaction, Bonferroni's post hoc test was used to evaluate intergroup comparisons. Student's paired t-test for independent samples was applied for comparison between CXCL1-transfected leg and collateral leg. The significance level for all comparisons was set at P Ͻ 0.05. Data are presented as means Ϯ SE.
RESULTS
Generation of Muscle CXCL1-Overexpressing Mice
Transgenic CXCL1 mice were generated by gene electrotransfer into the tibialis cranialis muscle. After treatment, the mice were assigned to either normal chow (ND) or a high-fat diet (HFD; 60 kcal% fat) ad libitum until termination of the experiment. After 3 mo of doxycycline administration, which induces transgenic expression, muscle CXCL1 mRNA expression showed a 2.1-fold increase in lean (P Ͻ 0.01) and a 1.5-fold increase in high-fat-fed mice (P Ͻ 0.05) compared with nontransfected control mice (Fig. 1A) . Also, serum CXCL1 was elevated significantly in the CXCL1-transfected animals (ND: 89.9 Ϯ 5.3 pg/ml; HFD: 98.1 Ϯ 12.7 pg/ml) compared with nontransfected control mice (ND: 58.1 Ϯ 4.9 pg/ml, P Ͻ 0.05; HFD: 65.8 Ϯ 6.8 pg/ml, P Ͻ 0.05) (Fig. 1B) .
No difference in serum levels of different pro-and antiinflammatory cytokines, including IL-10, IL-1␤, TNF␣, INF␥, IL-6, and IL-12, between transfected and nontransfected animals was observed (data not shown).
Overexpression of Muscle CXCL1 Attenuates Diet-Induced Fat Accumulation
To investigate the metabolic consequences of increased muscle and serum CXCL1, the metabolic phenotype was examined in the CXCL1-transfected animals by monitoring body weight, body composition, food intake, and glucose and insulin tolerance (Figs. 2 and 3 and Table 1 ). In the chow-fed groups, no difference in body weight between control and CXCL1-overexpressing mice was observed 3 mo after the transfection. In contrast, CXCL1-transfected mice fed a highfat diet had significantly lower body weight (33.3 Ϯ 1.1 g) compared with the high-fat-fed control mice (36.9 Ϯ 0.8 g, P Ͻ 0.05). As expected, all the high-fat-fed mice gained more subcutaneous and visceral fat compared with chow-fed mice. Interestingly, this accumulation of fat mass in the high-fat-fed animals was reduced significantly in CXCL1-transfected mice compared with the nontransfected control group when measured 3 mo after the transfection. This was expressed as a significant reduction in the accumulation of visceral fat in CXCL1-transfected animals (1,277.5 Ϯ 107.2 mg) compared with control mice (1,889.5 Ϯ 147.1 mg, P Ͻ 0.01) and in accumulation of subcutaneous fat in CXCL1-transfected mice (494.8 Ϯ 51.2 mg) compared with control mice (637.2 Ϯ 40.8 mg, P Ͻ 0.05) after 3 mo of high-fat feeding. It is likely that Fig. 1 . Chemokine CXC motif ligand 1 (CXCL1) electrotransfer increases serum CXCL1 and CXCL1 mRNA expression in transfected tibialis cranialis muscle. Mice were electrotransferred with 10 g of CXCL1 plasmid into the tibialis cranialis muscle and euthanized after 3 mo. Muscle CXCL1 mRNA expression (A) and serum CXCL1 (B) were measured in the CXCL1-transfected and saline-treated control mice (control) fed a normal chow (ND) or high-fat diet (HFD). CXCL1 mRNA expression is normalized to the expression level of 18S. The relative expression of CXCL1 mRNA is presented as fold change from the control group (control) fed normal chow. Data are presented as means Ϯ SE (n ϭ 16). Statistical significance was tested by 2-way ANOVA with Bonferroni's post hoc test. The 2-way ANOVA proved significant for both CXCL1 mRNA (P Ͻ 0.001) and serum CXCL1 (P Ͻ 0.001). *Statistical significance different from control mice (control) at P Ͻ 0.05 in the Bonferroni's post hoc tests. **P Ͻ 0.01. this effect on fat mass could account for the lower body weight of CXCL1-transfected mice observed at the end of the experiment. Also, CXCL1-overexpressing mice fed regular chow accumulated less visceral fat (VAT; 210.9 Ϯ 29.6 mg) and less subcutaneous fat (SAT; 97.7 Ϯ 15.1 mg) compared with chowfed control mice (VAT 326.2 Ϯ 35.1 mg, P Ͻ 0.05, and SAT 146.6 Ϯ 46.8 mg, P Ͻ 0.05) (Fig. 2, A and B, and Table 1 ). The effect of muscle CXCL1 overexpression on fat mass was further substantiated by whole body DEXA and MR scans. Eight weeks after transfection, MR scans revealed that the proportion of body fat was significantly lower in chow-fed, CXCL1-transfected mice (20.1 Ϯ 1.2%) compared with chow-fed control mice (24.05 Ϯ 1.1%, P Ͻ 0.05) (Fig. 2C) , representing 4.6 Ϯ 0.4 and 5.7 Ϯ 0.4 g of fat, respectively. Also, DEXA scans revealed a significantly lower proportion of total body fat in chow-fed CXCL1-transfected mice (13.2 Ϯ 1.6%) than in chow-fed control mice (19.8 Ϯ 1.5%, P Ͻ 0.01) (Fig. 2D) 
No difference in total food intake was detected between control and CXCL1-transfected mice, indicating that the CXCL1-related reduction in fat accumulation was not associated with decreased food intake. No significant difference in the tibialis muscle mass or liver mass between CXCL1-transfected and control mice was detected in either the chow-fed or high-fat-fed group when determined by weight of the dissected organs (frozen) 3 mo after the transfection. Also, weight of transfected and nontransfected collateral muscle was similar between transfected mice and control mice ( Table 1) . As assessed by whole body DEXA and MR scan, no differences in total lean body mass between CXCL1-transfected mice and control mice existed (Fig. 2, E and F) .
The influence on insulin action was investigated by GTTs and ITTs performed 10 wk after CXCL1 transfection. In the chow-fed group, the CXCL1-transfected mice and control mice responded similarly when challenged with glucose. However, the high-fat-fed group revealed a CXCL1-specific improved response in glucose regulation compared with control mice (2-way ANOVA, P Ͻ 0.05; Fig. 3D ). In addition to impaired glucose tolerance, the high-fat-fed control mice showed reduced insulin sensitivity following insulin administration compared with the high-fat-fed, CXCL1-transfected animals (2-way ANOVA, P Ͻ 0.05; Fig. 3B ). Furthermore, in the high-fat-fed group a tendency toward lower basal plasma glucose levels in the CXCL1-transfected mice (9.9 Ϯ 0.8 mM) compared with the high-fat-fed control mice (10.7 Ϯ 0.8 mM, P ϭ 0.081) in response to 5-h fasting was observed (data not shown).
Overexpression of Muscle CXCL1 Improves the Ability to Oxidize Fatty Acids
To investigate the underlying cause of decreased accumulation of fat in the CXCL1-overexpressing mice, the oxidative capacity in the CXCL1-transfected muscles was assessed. Direct measurements of ␤-oxidation were performed in skeletal muscle homogenates prepared from in vivo CXCL1-transfected muscles, collateral muscles, and muscle from nontransfected mice 2 wk after transfection (Fig. 4A) . CXCL1-transfected muscles from chow-fed mice had a 2.2-fold higher oxidation of [ 14 C]palmitate compared with nontransfected muscles from control mice (P Ͻ 0.05). Also, when fed a high-fat diet, CXCL1-transfected muscles showed a twofold higher [ 14 C]palmitate oxidation compared with control animals (P Ͻ 0.05). Interestingly, the oxidative capacity did not differ significantly in the individual mouse between the CXCL1-transfected muscle and the collateral muscle. In fact, there was a general trend for a greater [ 14 C]palmitate oxidation in the collateral muscle (ND: 1.5-fold increase, P Ͻ 0.05; HFD: Fig. 2 . Overexpression of muscle CXCL1 reduces fat accumulation. Three months after CXCL1 electrotransfer into tibialis cranialis muscle, CXCL1-transfected and control mice (saline treated) were euthanized, and intact visceral (A) and subcutaneous adipose tissue (B) were dissected from nontransfected (control) and CXCL1-transfected mice fed a ND or HFD and weighted (n ϭ 16). In a similar study in which mice were electrotransferred with CXCL1 or an empty vector (control group) into the tibialis cranialis muscle, magnetic resonance (MR; C and E) and dual-energy X-ray absorptiometry (DEXA) scans (D and F) were performed 8 wk after transfection to measure total fat% (C and D) and lean body mass (E and F) (n ϭ 8). Data in C and D are depicted as %total body weight. All data are presented as means Ϯ SE. Overall statistical significance was tested by 2-way ANOVA. Intergroup comparison was analyzed with Bonferroni's post hoc test. *Statistical significance at P Ͻ 0.05 from the chow-fed control group. **P Ͻ 0.01. The 2-way ANOVA proved significant for reduced fat% in CXCL1-transfected animals for both the DEXA (P Ͻ 0.01) and MR scans (P Ͻ 0.05).
1.5-fold increase, P ϭ 0.218) compared with muscle from nontransfected mice.
To further investigate the hypothesis of a CXCL1-mediated increased muscular fatty acid oxidation explaining the reduced accumulation of fat, quantitative expression analysis of genes involved in fatty acid oxidation was performed 3 mo after in vivo CXCL1 transfection. Calculation of fold changes demonstrated a CXCL1-dependent increase in mRNA expression of cluster of differentiation 36 (CD36), carnitine palmitoyl-CoA transferase I (CPT I), and 3-hydroxyacyl-CoA dehydrogenase (HADH), which are all transcripts of enzymes important for fatty acid transport and mitochondrial ␤-oxidation in the muscle (Fig. 4, D-F) . Compared with controls, CXCL1-transfected muscles from chow-fed mice showed a 2.3-fold increase in CD36 mRNA expression (P Ͻ 0.01) and a 1.8-fold increase in HADH mRNA expression (P Ͻ 0.05). In the high-fat-fed Fig. 3 . Overexpression of muscle CXCL1 counteracts dietinduced impairment of insulin sensitivity. An insulin tolerance test (ITT; A and B) was conducted 10 wk after CXCL1 transfection (n ϭ 8). Plasma glucose was measured right before injection of insulin solution (0.5 U/kg insulin ip diluted in 0.9% saline, 0 min) and after 15, 30, and 60 min. Twelve weeks after CXCL1 electrotransfer, a glucose tolerance test (GTT; C and D) was conducted (n ϭ 8). Plasma glucose was measured right before injection of glucose solution (2 g/kg ip, 0 min) and after 30 and 120 min. All data are presented as means Ϯ SE. Statistical significance was tested by 2-way ANOVA. Overall effect of CXCL1 was observed in the ITT (ND: P Ͻ 0.01; HFD: P Ͻ 0.001) and the GTT (ND: P Ͻ 0.05; HFD: P Ͻ 0.05). Intergroup comparison was analyzed with Bonferroni's post hoc test. *Significance at P Ͻ 0.05 from the nontransfected group at the given time point. Data are presented as means Ϯ SE. CXCL1, chemokine CXC motif ligand 1. Body weight of control and CXCL1-transfected mice was measured at the beginning and at termination of the experiment (3 mo). Three months after transfection, intact organs were dissected and weighed (transfected and collateral tibialis cranialis muscle, liver, visceral fat, and subcutaneous fat). Food intake was measured weekly. P values indicate the statistical difference between CXCL1-transfected mice and the saline-injected control mice. Statistical significance was tested by use of Bonferroni's post hoc test, with correction for multiple comparisons.
group, mRNA expression was increased in the CXCL1-transfected mice with 2.2-fold for CD36 (P Ͻ 0.05), 2.1-fold for CPT I (P Ͻ 0.05), and 1.9-fold for HADH (P Ͻ 0.05) compared with nontransfected controls. Furthermore, a tendency toward a CXCL1-dependent increase in mRNA expression of the oxidative type 1 fiber marker MHC1/MYH7 (myosin heavy chain 1) was observed, whereas no difference in the expression of glycolytic muscle fiber type markers (MHCIIx/ MYH1 and MHCIIa/MYH2) existed between CXCL1-transfected muscle and control muscles (Fig. 4, G-I) . Fig. 4 . Overexpression of CXCL1 in the tibialis cranialis muscle increases fat oxidation. A: 2 wk after in vivo electrotransfer of 10 g of CXCL1 plasmid into tibialis cranialis muscle, oxidation of radiolabeled palmitate in muscle homogenate prepared from CXCL1-transfected and saline-treated (control) animals in the ND and HFD groups was determined (n ϭ 8). Three months after CXCL1 electrotransfer, serum free fatty acid (FFA; B) and glycerol (C) were determined (n ϭ 8). Also, mRNA expression of muscle cluster of differentiation 36 (CD36; D), carnitine palmitoyl-CoA transferase I (CPT I; E), 3-hydroxyacyl-CoA (HADH; F) (n ϭ 16), MYH1/MHCIIx (mysoin heavy chain; G), MYH2/MHCIIa (H), and MYH7/MHC1 (I) (n ϭ 8) was measured 3 mo after transfection. mRNA expression of target genes is normalized to the expression level of 18S. The relative mRNA expression is presented as fold change values proportional to the ND control group. All data are presented as means Ϯ SE. Statistical significance was tested by 2-way ANOVA, followed by Bonferroni's post hoc test. *Significance at P Ͻ 0.05. **P Ͻ 0.01. Difference in oxidation between CXCL1-transfected and collateral leg was tested with Student's paired t-test.
To elucidate whether the increased serum CXCL1 levels in the transfected animals could affect distant muscle tissue in an endocrine manner, we investigated the mRNA expression of the same genes in the nontransfected collateral tibialis cranialis muscle. In lean mice, the collateral muscle of the transfected mice showed increases of 1.5-fold for CD36 (P Ͻ 0.05) and 1.7-fold for CPT I (P Ͻ 0.05) compared with control mice. In high-fat-fed mice, the collateral leg of CXCL1-transfected animals showed increases of 2.5-fold for CD36 (P Ͻ 0.05) and 2.1-fold for HADH (P Ͻ 0.05) (data not shown). These results are in accord with the general trend of the collateral muscle also having increased ex vivo [
14 C]palmitate oxidation (Fig. 4A) .
To investigate substrate availability for the increased muscle fatty acid oxidation, we measured concentration of serum FFA and glycerol. In lean mice, no difference in concentration of either FFA or glycerol between control mice and CXCL1-transfected mice was detected (Fig. 4, B and C) . However, in the high-fat-fed group the CXCL1-transfected animals displayed lower serum levels of FFA (741.3 Ϯ 67.7 M) compared with the control mice (970.3 Ϯ 54.7 M, P Ͻ 0.05), which could likely be explained by the increased expression of fatty acid transporters for muscle uptake and increase in fatty acid oxidation mediated by overexpression of CXCL1. On the contrary, the lipolytic product glycerol was elevated in serum from CXCL1-transfected animals (235 Ϯ 26.7 M) compared with control mice (194.5 Ϯ 13.9 M, P Ͻ 0.05), which could indicate an increase in lipolysis. In addition, an overall increase in serum glycerol with high-fat diet was detected (2-way ANOVA, P Ͻ 0.01). No overall increase in serum FFA with high-fat feeding was detected.
Overexpression of Muscle CXCL1 Induces Expression of Angiogenic Markers Locally in the Muscle
Because CXCL1 is a potent angiogenic factor (2), it was of interest to evaluate whether overexpression of CXCL1 induces angiogenesis in the muscle, contributing further to the increased oxidative capacity. To evaluate the angiogenic potential of elevated muscle CXCL1 mRNA expression, muscles electrotransferred with CXCL1 from a 5-wk CXCL1 overexpression experiment were dissected and stained for the endothelial marker CD31 (Fig. 5, C and D) . A slight, nonsignificant elevation in the number of interfibrillar capillaries in areas without degeneration was observed in some of the CXCL1-treated muscles. These areas were disclosed by positive CD31 staining. In the CXCL1-transfected muscle, areas of individual degenerating muscle fibers and infiltration of macrophages were also observed. These areas showed positive staining for CD31, suggesting that the chemotactic role of CXCL1 with recruitment of immune cells is linked to the presence of the endothelial marker CD31. To look further into the angiogenic effect of elevated muscle CXCL1 expression, muscle mRNA expression of VEGF and CD31 in mice transfected with CXCL1 was determined (Fig. 5, A and B) . As tested by two-way ANOVA, the overall effect of CXCL1 transfection on muscle VEGF mRNA expression was significant (P Ͻ 0.01) and not affected by diet. Muscle mRNA expression of VEGF in lean mice transfected with CXCL1 was 1.9-fold higher compared with nontransfected mice (P Ͻ 0.05). Correspondingly, the overall effect of CXCL1 transfection on muscle CD31 mRNA expression was also significant (2-way ANOVA, P Ͻ 0.01). In lean mice, a 1.7-fold increase in CD31 mRNA Fig. 5 . Angiogenic markers in CXCL1-overexpressing muscle. Muscle mRNA expression of VEGF (A) and CD31 (B) was measured in CXCL1-transfected and in saline-treated control mice fed HFD or ND 3 mo after muscle CXCL1 transfection. mRNA expression of target genes is normalized to the expression level of 18S. Gene expression is presented as fold change values relative to the saline-treated ND control mice. Data are presented as means Ϯ SE (n ϭ 16). Overall statistical significance was tested by 2-way ANOVA and intergroup comparison with Bonferroni's post hoc test. *Significance at P Ͻ 0.05. C and D: cross-sectional and longitudinal histological sections were performed from tibialis cranialis muscles excised 5 wk after CXCL1 electrotransfer and stained for CD31 (CD31, X400; n ϭ 6). Scale bar in D, bottom, is valid for all presented sections. Arrow indicates areas with capillary networks, which in D are associated with positive staining for the endothelial marker CD31. A slight indication of increased capillarity in CXCL1-transfected muscle was observed, but significant difference from saline-injected muscles could not be achieved.
expression compared with the nontransfected control group was detected (P Ͻ 0.05).
DISCUSSION
Cytokines, chemokines, and other peptides can be secreted by skeletal muscle cells, with the potential to act as hormones, either locally within the muscle or by targeting distant organs (25) . Several studies have established a role for these musclederived factors as important contributors of the beneficial metabolic effects of exercise. Here, we demonstrate a metabolic role of muscle-derived CXCL1, which we identified recently as an exercise factor in mice (26) . The main finding of the present study was that in vivo muscular overexpression of CXCL1 reduces diet-induced fat accumulation. In continuation, this effect was accompanied by a CXCL1-dependent increase in muscular ex vivo fatty acid oxidation and upregulation of genes involved in fatty acid oxidation and vascularization in the muscle.
We demonstrated recently that both muscle CXCL1 expression and serum CXCL1 are highly enhanced in response to a single bout of exercise, underscoring the role of CXCL1 as an exercise factor (26) . Because the focus has concentrated previously on characterizing the proinflammatory role of chemokines in disease, very little is known about their potential role in metabolism. In the present study, metabolic effects of elevated muscle and serum CXCL1 were investigated utilizing an in vivo mouse model with electrotransfer-mediated CXCL1 overexpression in the tibialis cranialis muscle. In this model, a significant increase in CXCL1 mRNA expression in the transfected muscle was obtained, which persisted at least 3 mo after transfection (Fig. 1A) . In line with this, the level of serum CXCL1 was elevated in the transfected mice compared with control mice (Fig. 1B) . Importantly, these transfection-induced levels of serum and muscle CXCL1 are comparable and within the normophysiological range observed in response to a single bout of exercise (20, 26) . It is of note that a single bout of exercise induces only a transient increase in muscle and serum CXCL1 (26) . Accordingly, a constantly elevated CXCL1 expression, which is expected in this model, may not induce the exact same adaptive effects as the exercise-induced regular peaks of CXCL1 in muscle and serum.
Interestingly, the CXCL1-transfected mice accumulated significantly less visceral and subcutaneous fat during 3 mo of either high-fat feeding or chow feeding (Fig. 2, A and B, and Table 1 ). Of note, this effect was not associated with a concomitant decrease in food intake, emphasizing a direct impact of CXCL1 on fat metabolism. Importantly, we found a significant reduction in fat accumulation by CXCL1 overexpression regardless of doxycycline treatment or mock transfection.
As assessed by ITT and GTT, the CXCL1-transfected mice also showed indications of improved glucose tolerance and insulin responsiveness (Fig. 3) . In support of this, it has been demonstrated that the chemokine CXC motif receptor 2 (CXCR2) antagonist SB-225002 suppresses electrical stimulation-evoked, insulin-stimulated GLUT4 translocation in a contractile C 2 C 12 myotube model (20) . Hence, it is tempting to speculate that CXCL1, acting in an autocrine manner through CXCR2, contributes to insulin-stimulated increased glucose clearance in muscles. However, because treatment of C 2 C 12 myotubes with CXCL1 alone is insufficient to induce measurable effects on GLUT4 translocation (21) , it may seem more likely that the observed effect of CXCL1 on glucose metabolism is indirect through an effect on fat mass.
The reduced accumulation of fat in the CXCL1-transfected mice, which was also recognized by MR and DEXA measurement of total body fat mass (Fig. 2, C and D) , prompted us to investigate oxidative capacity in the muscles of these mice. Interestingly, we found that muscles transfected with CXCL1 displayed significant improvements in fatty acid oxidation as assessed by ex vivo palmitate turnover (Fig. 4A) . This result was further substantiated by a CXCL1-dependent upregulation of CD36, CPT I, and HADH mRNA expression in the transfected muscles (Fig. 4, D-F) . In addition, we found a tendency toward increased MHC1/MYH7 mRNA expression, which combined with the other results further supports a CXCL1-mediated improvement of the oxidative capacity in the muscles (Fig. 4I) . Of note, the intramitochondrial enzyme HADH catalyzes the penultimate step in fatty acid oxidation, and the mitochondrial contents of CPT I and FAT/CD36 have been positively correlated with mitochondrial fatty acid oxidation rates in skeletal muscle (3, 6, 33, 34) . Muscle contraction and training have been shown to enhance the relative level of FAT/CD36 protein (34) and the mRNA expression of HADH (28) and CPT I (27) . Similarly, we found that the CXCL1 receptor CXCR2 is significantly upregulated in muscle tissue in response to an acute bout of exercise (data not shown), further suggesting the importance of a CXCR2 agonist like CXCL1 in mediating an autocrine or paracrine effect on FFA metabolism in the contracting muscle. Importantly, expression of CPT I, CD36, and HADH was also enhanced in the collateral muscle of CXCL1-transfected mice compared with muscles from nontransfected animals (data not shown). In line with this, ex vivo fatty acid oxidation in the collateral muscles of the CXCL1-transfected chow-fed mice was upregulated compared with control animals (Fig. 4A) . It is likely that this effect could be ascribed to the increased level of plasma CXCL1 (Fig. 1B) , with CXCL1 acting in an endocrine manner on distant muscle tissue. Thus an overall effect of elevated serum CXCL1 on fatty acid oxidation in skeletal muscle tissue could likely account for the observed attenuation of diet-induced fat accumulation in these animals.
Both FFA and glycerol in plasma have been used as rough estimates of lipolysis and mobilization of fatty acid from adipose tissue (40, 41 ). Interestingly, the plasma level of glycerol was elevated in the CXCL1-transfected mice, suggesting an increased rate of lipolysis in these animals (Fig. 4C) . Plasma FFA and glycerol concentrations represent a balance between FFA and glycerol release into plasma and their uptake by peripheral tissues. Because glycerol liberated by lipolysis is not reincorporated into triglyceride within the adipocytes, plasma glycerol concentration has been interpreted as a more precise indicator of accelerated lipolysis than plasma FFA (7, 15) . In contrast to the increase in serum glycerol, serum FFA level in the transfected animals was lower compared with controls (Fig. 4B) . Because serum FFA level is also affected by peripheral uptake into skeletal muscle, this may suggest an enhanced peripheral FFA uptake in the CXCL1-transfected animals compared with control animals. This hypothesis is further substantiated by the augmented expression of CD36 (Fig. 4D ), which appears to be the primary fatty acid trans-porter responsible for FFA uptake into skeletal muscle (3) . In line with this, Goudriaan et al. (11) have shown that CD36-deficient mice exhibit increased plasma FFA amount. Taken together, the lower amount of adipose tissue in the CXCL1-transfected animals may likely be explained by a result of an enhanced uptake of FFA for increased FFA oxidation in the muscle and a concomitant increased state of lipolysis.
In addition to the expression of enzymes involved in FFA oxidation, the capacity to oxidize FFA also depends on the delivery of substrate and oxygen and, therefore, on perfusion/ capillarization of the skeletal muscle. Human IL-8, which is recognized as a functional counterpart of murine CXCL1, is suggested to take part in this process through activation of the CXCR2 receptor (1), which is expressed by muscle tissue (data not shown), and to a great extent on microvascular endothelial cells (19, 32) . Different studies have demonstrated the angiogenic potential of CXCL1 in ischemia, wound healing, and cancer growth (18) , and it is well known that the CXC ELRϩ chemokines are all potent inducers of angiogenesis in general (1, 2) . However, scientific evidence of the involvement of muscle-derived CXCL1 in angiogenesis in muscle tissue has not yet been established. A slight indication of increased capillarity in CXCL1-transfected muscle was observed, but significant difference from saline-injected muscles could not be achieved (Fig. 5, C and D) . However, the potential effect of CXCL1 on capillarization was indicated by a marked increase in muscle mRNA expression of both CD31 and the potent angiogenic factor VEGF in the CXCL1-transfected mice (Fig.  5, A and B) . The mechanism whereby the CXC ELRϩ chemokines induce angiogenesis through CXCR2 activation has not been fully clarified. The observed CXCL1-dependent increase in VEGF production definitely suggests that the angiogenic effect of CXCL1 is at least partly mediated through induction of VEGF. This is further supported by a previous study in which use of anti-VEGF-A antibodies in mice abrogated CXCL1-induced angiogenesis (31) . In addition, both IL-8 (17) and human GRO␣ (which shares high-sequence homology with murine CXCL1) (38) and CXCR2 receptor activation in general (39) have been suggested to activate NF-B signaling, which in turn, at least in mice, is hypothesized to induce VEGF (17) . Accordingly, this implies that CXCL1 increases VEGF expression through activation of NF-B.
In summary, we have examined the metabolic consequences of a long-term increase in skeletal muscle and serum CXCL1 in mice selectively overexpressing CXCL1 in the tibialis cranialis muscle. The CXCL1-dependent augmentation of fatty acid oxidation, the associated enhanced mRNA expression of enzymes important for fatty acid oxidation, and a likely positive effect on muscle capillarization strongly imply a role of CXCL1 in improving fatty acid oxidation in the muscle. In line with this, the effect on whole body fat accumulation definitely underscores the physiological significance of the increase in muscle CXCL1 expression that occurs, for instance, in response to a bout of exercise.
